How Long-Term Use of Proton Pump Inhibitors May Affect Bone Health

For millions of people living with chronic heartburn or gastroesophageal reflux disease (GERD), proton pump inhibitors (PPIs) offer reliable relief. Medications such as omeprazole, pantoprazole, and esomeprazole are among the most commonly used drugs worldwide, available both by prescription and over the counter. While generally considered safe, concerns have emerged over the past decade about their long-term

PPIs are widely used to treat chronic heartburn and GERD.

use. Researchers have begun examining whether extended PPI therapy may be linked to decreased bone density and a higher risk of fractures. Although these medications remain highly effective for acid-related disorders, understanding their potential impact on bone health is important for patients who rely on them daily.

PPIs reduce stomach acid by blocking the enzyme system responsible for acid secretion in the stomach lining. This suppression helps relieve reflux symptoms and allows irritated tissues to heal. However, stomach acid also plays a role in nutrient absorption - particularly calcium. Calcium requires an acidic environment for optimal absorption,

Reduced calcium absorption over time may contribute to lower bone density.

especially from dietary sources like dairy products. When acid production is significantly reduced over long periods, calcium absorption may decrease. Over time, insufficient calcium levels can contribute to reduced bone mineral density, potentially increasing the risk of osteoporosis. While the exact biological mechanism is still being studied, this disruption in mineral absorption is one leading explanation for the observed association between chronic PPI use and bone changes.

Large observational studies have reported an association between long-term PPI use and an increased risk of fractures, particularly hip, spine, and wrist fractures. Some analyses suggest that individuals who take high doses of PPIs for a year or more may face a modestly elevated fracture risk compared to non-users. It is important to note, however, that most of these studies show correlation rather than direct

Hip and spine fractures are among the injuries most commonly studied in PPI research.

causation. Many people who take PPIs long term may already have other risk factors for bone loss, such as advanced age, limited physical activity, smoking, or chronic medical conditions. Because of this, researchers continue to evaluate whether PPIs independently contribute to fracture risk or whether the association reflects underlying health differences in those who use them.

Despite these concerns, PPIs remain an essential treatment for many patients, especially those with severe GERD, Barrett's esophagus, or a history of gastrointestinal bleeding. The key issue is not avoiding PPIs altogether, but using them appropriately. Healthcare providers often recommend the lowest effective dose for the shortest necessary duration. For individuals who require long-term therapy, clinicians may suggest monitoring bone health, ensuring adequate calcium and vitamin D intake, and encouraging weight-bearing exercise. In some cases, switching to alternative acid-suppressing medications or reassessing the need for continuous therapy may also be appropriate. Individualized care, rather than abrupt discontinuation, is critical to balancing digestive health with skeletal protection.

PPIs have transformed the management of acid-related disorders and continue to improve the quality of life for many patients. However, like all medications, they are not without potential risks. Emerging research suggests that long-term use may be associated with reduced bone density and a slightly higher risk of fractures,

Weight-bearing exercise and adequate calcium intake help support bone health.

particularly in vulnerable populations. By staying informed, discussing the duration of therapy with healthcare providers, and supporting bone health through nutrition and lifestyle choices, patients can use these medications safely and responsibly. The goal is not alarm, but awareness - ensuring that effective treatment today does not compromise health in the future.

References

Yu, Elaine W., et al. “Proton Pump Inhibitors and Risk of Fractures: A Meta-Analysis of 11 International Studies.” The American Journal of Medicine, vol. 124, no. 6, Jun. 2011, pp. 519–26, doi:10.1016/j.amjmed.2011.01.007.

Hansen, Karen E., et al. “Do Proton Pump Inhibitors Decrease Calcium Absorption?” Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research, vol. 25, no. 12, Dec. 2010, pp. 2786–95, doi:10.1002/jbmr.166.

Center for Drug Evaluation and Research. “FDA Drug Safety Communication: Possible Increased Risk of Fractures of the Hip, Wrist, and Spine with the Use of Proton Pump Inhibitors.” U.S. Food and Drug Administration, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-possible-increased-risk-fractures-hip-wrist-and-spine-use-proton-pump. Accessed 13 Feb. 2026.

Maideen, Naina Mohamed Pakkir. “Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors.” Chonnam Medical Journal, vol. 59, no. 2, May 2023, pp. 115–27, doi:10.4068/cmj.2023.59.2.115.

Assessed and Endorsed by the MedReport Medical Review Board